Is it safe to use topical NSAIDs for corneal sensitivity in Sjogren's syndrome patients?

被引:10
|
作者
Aragona, Pasquale [1 ]
Di Pietro, Rossana [1 ]
机构
[1] Univ Messina, Policlin G Martino, Dept Surg Specialties, Sect Ophthalmol,Ocular Surface Dis Unit, I-98125 Messina, Italy
关键词
corneal sensitivity; cyclooxygenase; diclofenac; flurbiprofen; indomethacin; ketorolac tromethamine; nonsteroidal anti-inflammatory drugs; ocular surface; Sjogren's syndrome;
D O I
10.1517/14740338.6.1.33
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Sjogren's syndrome dry eye is an inflammatory disease accompanied by an impairment of the autonomous nervous system of the ocular surface. The therapy for this condition is shifting from the mere tear replacement to a more complex approach including an anti-inflammatory treatment. Clinical trials have evidenced that the use of NSAIDs is followed by a reduction of the ocular discomfort symptoms in dry-eye patients. However, sporadic case reports of corneal melting in dry-eye subjects who underwent surgical procedures has brought attention to the possible effect that NSAIDs may have on corneal sensitivity. Therefore, the effect of NSAID treatment on corneal sensitivity in normal subjects and in patients with dry eye was studied. The results of these trials seem to demonstrate that some NSAIDs, diclofenac in particular, have the effect of reducing corneal sensitivity both in normal subjects and in patients with dry eye. Therefore, NSAIDs should be used with caution in Sjogren's syndrome patients.
引用
收藏
页码:33 / 43
页数:11
相关论文
共 50 条
  • [21] Secretagogue Use in Patients with Primary Sjogren's Syndrome
    Noaiseh, Ghaith
    Baker, Joshua
    Vivino, Frederick B.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S927 - S927
  • [22] Increased corneal sub-basal nerve density in patients with Sjogren syndrome treated with topical cyclosporine A
    Levy, Ora
    Labbe, Antoine
    Borderie, Vincent
    Hamiche, Taous
    Dupas, Benedicte
    Laroche, Laurent
    Baudouin, Christophe
    Bouheraoua, Nacim
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2017, 45 (05): : 455 - 463
  • [23] Evaluation of corneal layers and anterior sclera in patients with primary Sjogren's syndrome
    Pekel, Gokhan
    Tasci, Murat
    Bahar, Alperen
    Pekel, Evre
    Cetin, Ebru Nevin
    Martin, Cigdem
    Cobankara, Veli
    ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 2019, 82 (04) : 270 - 274
  • [24] The role of Vitamin D in Sjogren's Syndrome patients with corneal neuropathy.
    Rivera, Trenton
    O'Sullivan, Ryan
    Alvarez, Mauricio
    Bunya, Vatinee Y.
    Masssaro-Giordano, Giacomina
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [25] Long-term Corneal Complications in Patients with Primary Sjogren's Syndrome
    Gire, Anisa
    Mathews, Priya
    Cui, David
    Akpek, Esen K.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [26] Topical cyclosporine a (0.05%) treatment in dry eye patients: a comparison study of Sjogren's syndrome versus non-Sjogren's syndrome
    Cubuk, Mehmet Ozgur
    Ucgul, Ahmet Yucel
    Ozgur, Armagan
    Ozulken, Kemal
    Yuksel, Erdem
    INTERNATIONAL OPHTHALMOLOGY, 2021, 41 (04) : 1479 - 1485
  • [27] Topical cyclosporine a (0.05%) treatment in dry eye patients: a comparison study of Sjogren’s syndrome versus non-Sjogren’s syndrome
    Mehmet Ozgur Cubuk
    Ahmet Yucel Ucgul
    Armagan Ozgur
    Kemal Ozulken
    Erdem Yuksel
    International Ophthalmology, 2021, 41 : 1479 - 1485
  • [28] Are NSAIDs safe to use in post-MI patients?
    Michael T. Nurmohamed
    Nature Reviews Rheumatology, 2011, 7 : 561 - 562
  • [29] Corneal innervation and morphology in primary Sjogren's syndrome
    Tuominen, ISJ
    Konttinen, YT
    Vesaluoma, MH
    Moilanen, JAO
    Helintö, M
    Tervo, TMT
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 (06) : 2545 - 2549
  • [30] Bilateral corneal melting associated with topical diclofenac 0.1% after cataract surgery in a patient with Sjogren's syndrome
    Tu, Pei-Ning
    Hou, Yu-Chih
    TAIWAN JOURNAL OF OPHTHALMOLOGY, 2019, 9 (03) : 202 - 205